Posters

Successful management of interferon-associated retinopathy by intravitreal injection of bevacizumab

Poster Details

First Author: L.Wang TAIWAN

Co Author(s):    Y. Lee   T. Kao                          

Abstract Details



Purpose:

To describe 2 cases of successful management of severe Interferon-associated retinopathy by repeated monthly intravitreal injections of bevacizumab.

Setting:

Hospital Based/ Ophthalmology Department of National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan

Methods:

We report 2 patients of severe Interferon-associated retinopathy who were undergoing chronic hepatitis C treatment. Both patients complained of progressive blurred vision during the Interferon treatment in their affected eyes. Diffuse cotton wool spot, retinal haemorrhages, and macular edema were noted in both patients. One of the patients also had profound optic disc swelling. They had only 3 months and 2 months respectively to complete their course of Interferon treatment for hepatitis C. We treated the patients with monthly intravitreal injection of bevacizumab until the Interferon treatment course completed.

Results:

Clinical course, visual acuity, fundus photos, and fluorescein angiography were monitored carefully. These 2 patients underwent 3 times and 2 times of intravitreal injections of bevacizumab respectively. The visual acuity of their affected eyes both improved to 20/20 with dramatic resolution of retinal haemorrhage, cotton wool spot, macular edema, and disc swelling. They both completed their Interferon treatment for hepatitis C. We followed up them for more than 2 years and their retina remained stable without any deterioration of visual acuity.

Conclusions:

For patients with severe Interferon-associated retinopathy, discontinuance of the interferon therapy is not the only solution. Intravitreal injections of bevacizumab can be considered as an adjuvant therapy to help these patients complete the course of Interferon treatment. Careful and frequent follow up is mandatory in such patients.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy